The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Boothwyn Pharmacy (NRP 1963) would like to inform you that during routine post-release testing, a CAPA investigation revealed that manufacturer-provided calibrations on certain vessels did not meet expected tolerances. As a result, specific lot(s) of our compounded products did not meet potency specifications.

Boothwyn has notified patients directly to immediately examine their products quarantine and return the product subject to recall to us. We also notified them to please discontinue use of this product if they still have any unused medication.

Boothwyn takes this matter seriously and are committed to earning and maintaining trust in our operations through transparency, accountability, and action. As part of our commitment to quality, we have already implemented enhanced safeguards, including ensuring all required potency, sterility, and endotoxin testing results are received by the pharmacy, and passing, before any product leaves our facility.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Lot Number	Product	Type	Exp. Date	Dispensed (# Rxs)	Date Shipped
03202025@4	Semaglutide 2.5 mg/mL Inj. Vial	Human	7/18/25	177	3/25/25
06092025@23	Fluorescein 2% Ophth Sol.	Human	9/9/25	8	6/9/25